Literature DB >> 24690956

The role of microbiota in hepatic encephalopathy.

Jasmohan S Bajaj1.   

Abstract

Hepatic encephalopathy (HE), which consists of minimal (MHE) and overt (OHE) stages, is a model for impaired gut-liver-brain axis in cirrhosis. Microbiota changes in both stages have been associated with impaired cognition, endotoxemia, and inflammation. There is dysbiosis (reduced autochthonous taxa [Lachnospiraceae, Ruminococcaceae, and Clostridiales XIV] and increased Enterobacteriaceae and Streptococcaceae) with disease progression. In MHE, there is an increased abundance of Streptococcus salivarius linked to cognition and ammonia. In OHE, stool Alcaligenaceae and Porphyromonadaceae are associated with poor cognition. Colonic mucosal microbiome in cirrhosis is significantly different compared with stool and independently related to cognition. HE treatment can affect microbial composition and function; cognitive improvement in MHE after rifaximin, a non-absorbable antibiotic, occurred without significant stool microbiota composition change but improved metabolic linkages. Similarly, there are only modest lactulose and rifaximin-associated changes on microbiota composition in OHE. HE represents an important model to study microbiome-brain interactions.

Entities:  

Keywords:  cirrhosis; correlation network; covert hepatic encephalopathy; dysbiosis; endotoxin; lactulose; minimal hepatic encephalopathy; probiotic; rifaximin; systemic inflammation

Mesh:

Year:  2014        PMID: 24690956      PMCID: PMC4153779          DOI: 10.4161/gmic.28684

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


  42 in total

1.  Colonic microbiome is altered in alcoholism.

Authors:  Ece A Mutlu; Patrick M Gillevet; Huzefa Rangwala; Masoumeh Sikaroodi; Ammar Naqvi; Phillip A Engen; Mary Kwasny; Cynthia K Lau; Ali Keshavarzian
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-01-12       Impact factor: 4.052

2.  Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients.

Authors:  O Riggio; M Varriale; G P Testore; R Di Rosa; E Di Rosa; M Merli; A Romiti; C Candiani; L Capocaccia
Journal:  J Clin Gastroenterol       Date:  1990-08       Impact factor: 3.062

3.  Characterization of fecal microbial communities in patients with liver cirrhosis.

Authors:  Yanfei Chen; Fengling Yang; Haifeng Lu; Baohong Wang; Yunbo Chen; Dajiang Lei; Yuezhu Wang; Baoli Zhu; Lanjuan Li
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

Review 4.  The model for end-stage liver disease (MELD).

Authors:  Patrick S Kamath; W Ray Kim
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

5.  Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study.

Authors:  Manuel Romero-Gómez; María Jover; José A Del Campo; José L Royo; Elena Hoyas; José J Galán; Carmina Montoliu; Eugenia Baccaro; Mónica Guevara; Juan Córdoba; Germán Soriano; José M Navarro; Carmen Martínez-Sierra; Lourdes Grande; Antonio Galindo; Emilia Mira; Santos Mañes; Agustín Ruiz
Journal:  Ann Intern Med       Date:  2010-09-07       Impact factor: 25.391

6.  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Authors:  Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

7.  Muscle wasting is associated with mortality in patients with cirrhosis.

Authors:  Aldo J Montano-Loza; Judith Meza-Junco; Carla M M Prado; Jessica R Lieffers; Vickie E Baracos; Vincent G Bain; Michael B Sawyer
Journal:  Clin Gastroenterol Hepatol       Date:  2011-09-03       Impact factor: 11.382

8.  Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing.

Authors:  Zhigang Zhang; Huiqin Zhai; Jiawei Geng; Rui Yu; Haiqing Ren; Hong Fan; Peng Shi
Journal:  Am J Gastroenterol       Date:  2013-07-23       Impact factor: 10.864

9.  Altered profile of human gut microbiome is associated with cirrhosis and its complications.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; Phillip B Hylemon; Arun J Sanyal; Melanie B White; Pamela Monteith; Nicole A Noble; Ariel B Unser; Kalyani Daita; Andmorgan R Fisher; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  J Hepatol       Date:  2013-12-25       Impact factor: 25.083

10.  Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; Arun J Sanyal; Phillip B Hylemon; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Jason M Ridlon; Kalyani Daita; Pamela Monteith; Nicole A Noble; Melanie B White; Andmorgan Fisher; Masoumeh Sikaroodi; Huzefa Rangwala; Patrick M Gillevet
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more
  47 in total

1.  Beneficial effects of LRP6-CRISPR on prevention of alcohol-related liver injury surpassed fecal microbiota transplant in a rat model.

Authors:  Linghua Yu; Linlin Wang; Huixing Yi; Xiaojun Wu
Journal:  Gut Microbes       Date:  2020-03-13

Review 2.  PET and MR imaging of neuroinflammation in hepatic encephalopathy.

Authors:  Yun Yan Su; Gui Fen Yang; Guang Ming Lu; Shawn Wu; Long Jiang Zhang
Journal:  Metab Brain Dis       Date:  2014-12-17       Impact factor: 3.584

3.  Influence of proton pump inhibitors on microbiota in chronic liver disease patients.

Authors:  Kenta Yamamoto; Masatoshi Ishigami; Takashi Honda; Tomoaki Takeyama; Takanori Ito; Yoji Ishizu; Teiji Kuzuya; Kazuhiko Hayashi; Hidemi Goto; Yoshiki Hirooka
Journal:  Hepatol Int       Date:  2019-02-08       Impact factor: 6.047

Review 4.  Probiotics in management of hepatic encephalopathy.

Authors:  Barjesh Chander Sharma; Jatinderpal Singh
Journal:  Metab Brain Dis       Date:  2016-04-28       Impact factor: 3.584

Review 5.  Diet, gut microbiota and cognition.

Authors:  Cicely Proctor; Parameth Thiennimitr; Nipon Chattipakorn; Siriporn C Chattipakorn
Journal:  Metab Brain Dis       Date:  2016-10-05       Impact factor: 3.584

Review 6.  Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease-one of a kind or two different enemies?

Authors:  Christine Pocha; Chencheng Xie
Journal:  Transl Gastroenterol Hepatol       Date:  2019-10-09

7.  Most Individuals With Advanced Cirrhosis Have Sleep Disturbances, Which Are Associated With Poor Quality of Life.

Authors:  Marwan Ghabril; Mollie Jackson; Raghavender Gotur; Regina Weber; Eric Orman; Raj Vuppalanchi; Naga Chalasani
Journal:  Clin Gastroenterol Hepatol       Date:  2017-02-03       Impact factor: 11.382

Review 8.  Dysbiosis in the intensive care unit: Microbiome science coming to the bedside.

Authors:  Georgios D Kitsios; Michael J Morowitz; Robert P Dickson; Gary B Huffnagle; Bryan J McVerry; Alison Morris
Journal:  J Crit Care       Date:  2016-10-11       Impact factor: 3.425

Review 9.  What is new about diet in hepatic encephalopathy.

Authors:  Manuela Merli; Valerio Iebba; Michela Giusto
Journal:  Metab Brain Dis       Date:  2015-09-29       Impact factor: 3.584

Review 10.  Gut Microbiota and Hepatocellular Carcinoma.

Authors:  Xueme Tao; Nin Wang; Wenxi Qin
Journal:  Gastrointest Tumors       Date:  2015-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.